VERU

VERU INC. (The Female Health Company) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2010. The Company, formerly known as The Female Health Company, manufactures, markets, and sells the FC2 Female Condom, the only FDA-approved product under a woman's control for preventing unintended pregnancy and sexually transmitted infections (STIs), including HIV/AIDS. The Company completed its transition from the first-generation product (FC1) to the second-generation product (FC2) in October 2009, ceasing FC1 production and shifting manufacturing entirely to facilities in Malaysia and India.

Key Financial Metrics

Note: The Company had no outstanding borrowings under its Heartland Bank credit facility as of March 31, 2010.

Material Changes vs. Prior Period

• Revenue Mix and Volume: Net revenues were relatively flat compared to the prior year periods, despite a 26% increase in unit volume for the quarter and 23% for the six months. This was due to the complete shift to the lower-priced FC2 product (97-100% of sales mix) compared to the prior year's mix of FC1 and FC2.
• Gross Margin Expansion: Gross profit margins improved significantly to 58% (from 53% in the prior quarter and 50% in the prior six months) due to the lower production costs of the FC2 nitrile polymer compared to the FC1 polyurethane.
• Restructuring Costs: The six-month period included a one-time restructuring charge of $1,968,100 related to the cessation of FC1 manufacturing in the U.K., lease surrender payments, and facility exit costs. This significantly impacted operating income for the six-month period.
• Foreign Currency: The Company changed the functional currency of its U.K. and Malaysian subsidiaries to the U.S. dollar effective October 1, 2009. This reduced foreign currency volatility, resulting in a transaction loss of $79,449 for the six months ended March 31, 2010, compared to a gain of $999,820 in the prior year.
• Dividends: The Company initiated a quarterly cash dividend of $0.05 per share, paying approximately $1.4 million in February 2010 and declaring another for payment in May 2010.

Guidance, Outlook, and Risks

• Outlook: Management expects to incur up to an additional $25,000 in restructuring costs. The Company believes its current cash position is adequate to fund operations for at least the next twelve months.
• Non-GAAP Measures: Management highlights that excluding the one-time restructuring charge, operating income for the six months ended March 31, 2010, would have been $3,234,677, representing a 20% increase over the prior year.
• Risks:
  • Single Product Reliance: The Company derives virtually all revenue from the FC2 Female Condom.
  • Regulatory: FC2 is a Class III medical device; failure to comply with FDA regulations could result in withdrawal of approval.
  • Market Dependence: Success depends on public sector funding (e.g., USAID, UN agencies) and the ability of commercial partners to market the product effectively.
  • Liquidity: While currently liquid, the Company may need to raise additional capital or borrow under its credit facility if cash flows are insufficient to sustain dividends or operations.

Investor Verification Checklist

• Restructuring Completion: Verify the finalization of U.K. lease exit costs and the status of the remaining $733,670 restructuring accrual.
• Dividend Sustainability: Assess whether operating cash flows can sustain the new quarterly dividend policy of $0.05 per share alongside capital expenditures.
• Public Sector Orders: Monitor the timing and volume of large public sector orders (e.g., USAID, UN agencies) which drive revenue volatility.
• FC2 Market Penetration: Track the growth of commercial (private sector) sales versus public sector sales to evaluate diversification of revenue streams.
• Regulatory Compliance: Confirm ongoing compliance with FDA Class III device requirements and any new labeling or manufacturing mandates.